The white paper discusses the use of AnteoBind technology for evaluating SARS-CoV-2 variants in a Multiplex ACE2-RBD inhibition assay (RBDCoVACE2) performed at the NMI Natural and Medical Sciences Institute at the University of Tübingen, Germany. The findings were published in Nature Scientific Reports in a paper titled: COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants.
The Ellume AnteoTech relationship goes back over seven years. Ellume makes use of AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity in a number of tests, including Ellume’s COVID-19 Home Test. The two companies have a strong partnership and are actively discussing further development opportunities to deliver diagnostic solutions to the market.
The Anteo technology based magnetic particle hCG lateral flow assay produced a comparable limit of detection to the optimised colloidal gold reference assay of ~25 mIU/mL in urine. This confirms that particles conjugated with the Anteo Activation Reagent can rival traditionally used gold colloids in lateral flow applications and bring with it benefits associated with cost, handling and manufacturability improvements. The Anteo technology based hCG assay is 5 times more sensitive than the covalently conjugated magnetic particle based test using the same critical reagents.
For Ellume, there was an unmet and critical need for a faster, simpler, reliable way to diagnose and manage influenza. The technology that Ellume developed to meet this need evolved over several years and consisted of several layers of innovation. Investment in the core science has been significant and has resulted in multiple patent families with supporting national-phase applications. Around this core science, Ellume wrapped simple, intuitive user interfaces with smart-device connectivity to create unique products.
The Anteo protocol process is easy to follow and implement, and it takes the guesswork out of bioconjugation, thereby saving time and biological material. I like that the system emulates biology and takes advantage of many weak interactions versus one strong, covalent bond. I would definitely use Anteo’s technology again and would like to expand its use to our other lines of nanoparticles that we are developing for IVD.
We have used the Anteo's technology for the preparation of in-vitro diagnostic reagents. The Anteo method for immobilisation of antibodies is advantageous in many ways: it is much faster than many other methods; it is much easier than many other methods; last but not least it makes use of considerably fewer hazardous chemicals which in turn decreases the health risks and waste of hazardous chemicals.
We demonstrated the AMG Activation Kit is easy to use, which can contribute to decreased lot-to-lot variation of different assay productions, and provides an alternative chemistry for the immobilisation of challenging proteins.